Lo mejor del 2020: estudios que marcarán nuestra práctica clínica

• Paredes-Paucar, Cynthia ^[1] ; Chacón-Diaz, Manuel ^[2]
  1. [1] Instituto Nacional del Corazón Ignacio Chávez, México
  2. [2] Instituto Nacional Cardiovascular, INCOR Lima
• Localización: Revista Peruanos de Cardiología y Cirugía Cardiovascular, ISSN-e 2708-7212, Vol. 1, Nº. 4, 2020, págs. 200-205
• Idioma: español
• DOI: 10.47487/apcyccv.v1i4.101
• Títulos paralelos:
  • The best of 2020 studies that will mark our clinical practice
• Enlaces
  • Texto completo
• Referencias bibliográficas
  • Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China of novel coronavirus-infected pneumonia. N Engl J Med 2020;382: 1199–207....
  • Coronavirus resource center. Disponible en: COVID-19 Map - Johns Hopkins Coronavirus Resource Center (jhu.edu). Acceso 25 de diciembre, 2020.
  • Organización mundial de la salud, enfermedades cardiovasculares. Cardiovascular diseases (who.int). Acceso 25 de diciembre, 2020.
  • Tromp J, Bamadhaj S, Cleland J, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national...
  • Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with Empaglifozin in Heart Failure. N Engl J Med 2020 Oct 8;383(15):1413-24....
  • Packer M, Anker S, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection...
  • Armstrong P, Pieske B, Anstrom K, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020 May 14;382(20):1883-93....
  • Teerlink J, Diaz R, Felker G, et al. Cardiac Myosin activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2020 Nov 13....
  • Heerspink H, Stefansson B, Correa‑Rotter R, et al. Dapaglifozin in patients with Chronic Kidney disease. N Engl J Med 2020 Oct 8;383(15):1436-46....
  • Bhatt D, Szarek M, Steg P, et al. Sotaglifozin in patients with Diabetes and recent Worsening Heart Failure. N Engl J Med 2020 Nov 16. https://doi.org/10.1056/nejmoa2030183
  • Bhatt D, Szarek M, Pitt B, et al. Sotaglifozin in patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2020 Nov 16. https://doi.org/10.1056/nejmoa2030186
  • Anthony A. Bavry. Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with...
  • Solomon S, McMurray J, Anand I, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019...
  • FDA Briefing Document. NDA 207620 Sacubitril/Valsartan. Disponible en: download (fda.gov). Acceso 25 de diciembre 2020.
  • Klip I, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575–82.e3....
  • Ponikowski P, Kirwan B, Anker S, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind,...
  • Dangas G, Baber U, Sharma S, et al. Ticagrelor with aspirin or alone after complex PCI: the TWILIGHT-COMPLEX analysis. J Am Coll Cardiol 2020;75:2414–24....
  • Angiolillo D, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous...
  • Kim B, Hong S, Cho Y, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients...
  • Tardif J, Kouz S, Waters D, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019 Dec 26;381(26):2497-505....
  • Bouabdallaoui N, Tardif J, Waters D, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction...
  • Bavry A. Colchicine Cardiovascular Outcomes Trial – COLCOT. Disponible en: Colchicine Cardiovascular Outcomes Trial - American College of...
  • Nidorf S, Fiolet A, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020 Nov 5;383(19):1838-47. https://doi.org/10.1056/nejmoa2021372
  • Deepak L, Bhatt P, Steg G, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019 Jan 3;380(1):11-22....
  • Budoff M, Bhatt D, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides...
  • Borja, I. Stefan, J. et al. (2017). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment...
  • Collet J, Thiele H, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment...
  • Steg P. Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia – REALITY. Disponible en: Randomized...
  • Carson J. Myocardial Ischemia and Transfusion (MINT). Disponible en: Myocardial Ischemia and Transfusion - Full Text View - ClinicalTrials.gov....
  • Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):...
  • Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter...
  • Nijenhuis V, Brouwer J, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020...
  • Basel Ramlawi. Evolut Low Risk Bicuspid Study: Favorable Safety with TAVR in Patients with Bicuspid Valve. Disponible en: Evolut Low Risk...
  • Guimaraes H, Lopes R, de Barros P, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med...